Pfizer and its German partner Biontech announced the beginning of an intermediate study of the modified vaccine against the Covid-19, which is aimed at both the original and the Ba.2 of the Omicron strain.
It is noted that the vaccine is at the stage of initial study to collect more data.
Together, the fence of the Omikron Coronavirus strain Ba.4 and Ba.5, according to experts, make up almost 95% of the Covid-19 circulating options in the United States over the last week.